Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsDenver-Health-Medical-Plan Formulary Coverage & Pr…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentDenver-Health-Medical-PlanPolicy N/A

    DHMP Commercial Formulary — Pharmacy Coverage Criteria

    Customize your policy alerts

    Sign up for all Denver-Health-Medical-Plan policy alerts

    Know when Denver-Health-Medical-Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governance and use of the Denver Health Medical Plan (DHMP) Commercial Formulary for DHHA self-funded employee plans; explains selection, access, prior authorization (PAR) process, and coverage tiers for providers and members.

    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyDHMP Commercial Formulary — Pharmacy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a Prior Authorization Request (PAR) with clinical documentation to DHMP Pharmacy Department when a product is flagged PA/LA or exceeds quantity limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    closedformulary type
    4formulary tiers
    $0preventive copay
    requiredprior auth
    30-dayspecialty supply
    20+therapeutic classes

    Coverage criteria and formulary listings

    General coverage, authorization, and exclusions

    Covered when ALL of the following are met:

    Formulary coverage: Drug is listed on the DHMP Commercial Formulary and prescribed by a licensed provider; prescription required for pharmacy benefit coverage.

    Closed formulary — only listed drugs are covered (see formulary).

    Prior authorization / Exception: If the product row shows PA or LA, a prior authorization (PAR/exception request) must be submitted with clinical documentation; non-formulary drugs require trial of all reasonable formulary alternatives first (generic preferred where applicable).

    PARs reviewed case‑by‑case by DHMP Pharmacy Department; expedited review available for urgent situations. Contact DHMP Pharmacy Department at 303-602-2070 or 877-357-0963.

    Exclusions: Drug is not an excluded category (cosmetic agents, GLP-1s for weight loss, dietary supplements, blood/plasma except specified clotting factors, travel-only CDC vaccines, OTC drugs not listed, pigmenting/de-pigmenting products, therapeutic devices/appliances except formulary diabetic supplies, prescription vitamins except listed, investigational/experimental treatments).
    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyDHMP Commercial Formulary — Pharmacy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a Prior Authorization Request (PAR) with clinical documentation to DHMP Pharmacy Department when a product is flagged PA/LA or exceeds quantity limits.
    SourceLink
    On This Page
    Coverage criteria and formulary listingsProduct entries and coding / examplesPrior authorization, documentation, step therapy, and denial riskFormulary governance and scopeKey terms and abbreviationsStep therapy rules and required trialsQuantity limits and supply rulesDispensing location and mail-order rules

    Excluded items are not covered even with a PAR; see exclusions list for details.

    Formulary designations and step therapy

    Products carry per-row coverage flags; follow the designation shown in the formulary row.

    Coverage designations: Formulary rows may include one or more of the following flags: PA (prior authorization), LA (limited access), QL (quantity limit), ST (step therapy). Coverage is contingent on meeting the indicated flags.

    Apply the designation exactly as listed for each product.

    Step therapy example (inhaled agents): For agents labeled 'LA; ST' (e.g., umeclidinium-vilanterol), coverage requires documented failure of two of the following: budesonide/formoterol HFA inhaler; fluticasone/salmeterol blister or HFA inhaler; tiotropium HandiHaler or Spiriva Respimat.failure of 2 specified agents

    Exact agent list and ST wording appear in formulary product rows.

    Coverage contingent on prior auth / step therapy for select products

    Coverage for select products requires prior authorization or step-therapy documentation:

    LA/ST conditional coverage: Products labeled 'LA' or 'ST' require prior authorization and/or documented failure of specified alternatives before coverage (examples include DULERA and fluticasone furoate–vilanterol where failure of listed inhaled alternatives is required).

    Refer to the formulary row for the exact prior‑therapy requirements and acceptable alternatives.

    Coverage contingent on quantity limits

    Dispensing is limited when a QL is listed for the product:

    Quantity limit enforcement: When 'QL' appears next to a product, dispensing is limited to the stated quantity per time period (examples in this document include QL (6 per 1 day), QL (16 per 1 day), QL (40 per 1 day), QL (12 per 30 days)).

    Prescribers must request authorization for quantities exceeding the listed QL; pharmacy claims are matched to product/strength/QL.

    Formulary Tier Listings

    Selected formulary tier assignments and per-row requirements (as shown):

    Preventive tier listings: Multiple contraceptives, intrauterine devices, transdermal patches, and oral contraceptives are listed with Drug Tier = PREV; many rows show Requirements/Limits = . (no additional requirement specified in this segment).

    Individual product rows (chunks 234–243) list exact product names, tiers, and any Requirements/Limits.

    PAXLOVID limits

    Coverage and dispensing limits for PAXLOVID:

    PAXLOVID pack limits and age: PAXLOVID dose packs are covered subject to quantity limits per 28 days and a minimum age requirement.QL (20 per 28 days) for one pack size; QL (30 per 28 days) for alternate pack size; AGE (Min 18 Years)

    Apply the QL and minimum age exactly as shown in the formulary row (chunk 244).

    Hydrocortisone valerate

    Topical hydrocortisone valerate coverage conditions:

    Hydrocortisone valerate topical cream/ointment 0.2% is listed with limited access and a quantity limit.QL (2 per 1 day)

    Requirements/Limits = LA; QL (2 per 1 day) as shown in formulary (chunk 253).

    The formulary excludes certain categories of drugs from coverage even with a Prior Authorization Request (PAR). Excluded items include cosmetic use products (for example, anti-wrinkle, hair removal, and hair growth products), GLP‑1s when used for weight loss, dietary supplements, most over‑the‑counter drugs (unless the OTC product is listed on the formulary), blood or plasma products (except anti‑hemophilic factors VIII and IX), travel‑only CDC vaccines, pigmenting/de‑pigmenting agents, non‑formulary therapeutic devices or appliances (except formulary diabetic monitoring supplies), prescription vitamins (unless listed), and investigational or experimental treatments.

    This document fragment does not provide explicit clinical exclusion criteria beyond the formulary annotations. Coverage decisions in the shown product rows are expressed as utilization management flags (for example, PA, LA, ST, and QL), but no standalone clinical exclusion rules are stated in the excerpt.

    Within this partial section there are no explicit statements labeled “not medically necessary.” The excerpt presents per‑product Requirements/Limits entries (e.g., LA and QL flags for antimuscarinics) and utilization management controls, but does not include a separate not medically necessary policy declaration in the visible text.

    Product entries and coding / examples

    Refill eligibility (Non-controlled 75% used; Controlled 85% used)
    Refill eligibilityNon-controlled prescriptions eligible once 75% used; Controlled prescriptions eligible once 85% used (calculated from original directions).
    Quantity limits examples (QL examples listed)
    Glycopyrrolate (QL examples)oral solution 1 mg/5 ml: QL (45 per 1 day); oral tablets 1 mg and 2 mg: QL (45 per 1 day).
    Tiotropium (QL examples)HandiHaler 18 mcg capsules: QL (1 per 1 day); Respimat 1.25/2.5 mcg: QL (4 per 30 days).
    Lidocaine (QL examples)Lidocaine topical ointment 5%: QL (100 per 30 days); lidocaine-prilocaine topical cream/kits: typical requirement = 1.
    Quantity Limit examples (various examples)
    Antineoplastic examplesCapecitabine, imatinib, nilotinib, cyclophosphamide, etoposide — subject to PA/LA/QL as listed in formulary; see 'Antineoplastic Agents' group for specific product rules.
    MethotrexateMethotrexate included across oral and injectable formulations; QL/PA per plan for systemic oncology/rheumatology uses.
    PAXLOVID quantity limit examples
    PAXLOVID quantity limit examplesDose pack variants: 150 mg (10)/100 mg (10) and 300 mg (150 mg x2)-100 mg pack; QL examples: 20–30 per 28 days depending on pack; Age minimum 18 years.
    Hydrocortisone valerate topical QL
    Hydrocortisone valerate topical QLHydrocortisone valerate topical ointment 0.2%: Requirements/Limits = LA; QL (2 per 1 day).

    Prior authorization, documentation, step therapy, and denial risk

    Prior Authorization

    Prior authorization requirement

    Many drugs listed on the DHMP formulary require prior authorization (PA), step therapy (ST), limited access (LA), or quantity limits (QL). If the pharmacy rejects a claim indicating a PAR/exception is needed, providers should either submit a completed Prior Authorization Request (PAR) or change the prescription to a formulary alternative (therapeutic substitution). PARs must include clinical documentation (chart notes, relevant labs, treatment history) to justify the requested drug. Contact the DHMP Pharmacy Department for PAR submission or questions.

    • Submit PARs: Phone 303-602-2070 or 877-357-0963; Fax 303-602-2081; Email ManagedCarePAR@DHHA.org
    • PAR review: case-by-case using available criteria/guidelines; expedited reviews possible for urgent situations
    • If non‑formulary drug approved via PAR, cost = Tier 4 (non‑preferred brand) per Member Handbook
    Prior Authorization

    Prior authorization and utilization controls

    The formulary uses utilization management controls (PA, LA, QL, ST). Listings on the formulary will show these requirements and any specific criteria. Providers must follow the indicated PA/QL/LA/ST procedures for items flagged in the formulary to avoid claim denials.

    • PA = prior authorization required before DHMP will cover the drug
    • LA = limited access (may require filling at Denver Health Pharmacy or prior approval to fill elsewhere)
    • QL = quantity limits (per prescription or time frame)
    • ST = step therapy (documented trial/failure of required alternatives)
    Prior Authorization

    PA/LA/QL noted for TOBI PODHALER

    TOBI PODHALER (tobramycin inhalation capsules with inhalation device, 28 mg) is subject to Prior Authorization, Limited Access, and a Quantity Limit (QL 8 per 1 day). Ensure PA is obtained and claims match product name/strength/quantity.

    • Requirements/Limits: PA; LA; QL (8 per 1 day)
    • Denial risk if PA/LA/QL not met or claim does not match the listed product/strength/quantity
    Prior Authorization

    Prior authorization required for some products

    Several products across the formulary require prior authorization (examples include certain weight‑loss agents, specialty agents, and others). Review the formulary entry for Requirements/Limits and submit a PAR when indicated.

    • CONTRAVE ER: PA; LA; QL (4 per 1 day)
    • XIFAXAN: PA; LA; QL (6 per 1 day for 200 mg; 3 per 1 day for 550 mg)
    • CFTR modulators (e.g., ORKAMBI, TRIKAFTA): PA; LA; QL
    Prior Authorization

    Prior authorization/limited access required for flagged products

    Products flagged with LA or other special designations may require PA and have limited access — follow the formulary listing and DHMP PA process for these items to ensure coverage.

    • Examples: brimonidine‑timolol ophthalmic (LA; ST), many specialty biologics and injectables (PA; LA; QL)
    • Follow PA/QL/LA procedures listed in the formulary entry
    Step Therapy

    Prior authorization and step therapy for select antidepressants

    Some antidepressants and serotonergic/related agents have step therapy and/or prior authorization requirements. Document failure of required prior therapies per the formulary criteria when submitting a PAR.

    • Antidepressant examples: Certain serotonin modulators and other higher‑tier agents may require documented trials of first‑line agents
    • Provide treatment history and reasons for failure or intolerance when requesting PA
    Prior Authorization

    Prior authorization for select ophthalmic and antifungal products

    Select ophthalmic and antifungal products require prior authorization, limited access, and/or step therapy. Check the specific formulary entry and include prior therapy/failure documentation with PAR submissions.

    • Examples: CEQUA, XIIDRA (LA; ST; QL); JUBLIA (LA; ST require failure of ciclopirox nail)
    • Ketoconazole and other antifungals: follow formulary QL/PA indications
    Prior Authorization

    PA, LA, QL, and ST present across multiple agents

    Multiple agents across the formulary include combinations of PA, LA, QL, and ST. Providers must follow the documented requirements for each agent and provide supporting documentation when requesting authorization.

    • Examples include oncology, specialty inhaled products, and select oral targeted therapies with PA; LA; QL
    • Ensure claims match formulary product descriptors (name/strength/quantity)
    Prior Authorization

    Prior authorization required for certain LA antipsychotics

    Certain long‑acting (LA) injectable antipsychotics require prior authorization and step therapy (document failure of listed oral or IM alternatives). Provide prior trial documentation and dosing interval info with the PAR.

    • Examples: ABILIFY MAINTENA, ARISTADA, INVEGA SUSTENNA — Requirements/Limits = LA; ST (failure of oral agents); QL (per 28/56 days as listed)
    • Documentation: prior trial of indicated oral antipsychotics and rationale for LA formulation
    Prior Authorization

    PA/LA/QL requirements for specialty products

    Specialty products frequently have PA, LA, and QL requirements. Follow the specialty PA process and include complete clinical documentation and prior therapy history to support requests.

    • Examples: migraine biologics (Aimovig, Ajovy, Emgality) — PA; LA; QL per 28 days
    • Provide diagnosis, prior preventive therapy trials, and frequency of attacks where applicable
    Step Therapy

    Step therapy prior authorization

    Step therapy is used for many agents; some require documented trials and failures of specific drugs before approval. Submit documentation of the required failures when requesting PA.

    • Examples: BRIVIACT (ST: failure of two listed anticonvulsants); ENVARSUS XR (ST: failure of tacrolimus); inhaled combination products (ST failures as listed)
    • Therapeutic substitution: non‑formulary requests typically require trials of formulary alternatives first
    Note

    Contraceptive tier and limits

    Contraceptives are frequently listed as PREV (preventive) tier items with no PA indicated in many entries; however, review each formulary line for any specific Requirements/Limits.

    • Many oral contraceptives and intrauterine devices are Drug Tier = PREV and may have no PA
    • If no PA is listed, standard claim adjudication applies; contact Pharmacy Dept if uncertain
    Note

    Prior authorization presence not specified

    Some PREV‑tier items do not explicitly show PA requirements in the excerpt — when PA presence is not specified on the formulary line, follow normal claim processing or contact the DHMP Pharmacy Department for clarification.

    • If uncertain whether PA applies, call 303-602-2070 or 877-357-0963 or email ManagedCarePAR@DHHA.org
    Billing Rule

    Prior authorization / limits (examples)

    Certain items include age minimums, QLs, or other limits that must be observed. PAXLOVID, for example, has quantity limits and a minimum age requirement; claims outside those parameters may be denied.

    • PAXLOVID: QL (20 or 30 per 28 days depending on pack); AGE (Min 18 Years)
    • Ensure prescriptions meet age and quantity criteria before dispensing or submitting PAR
    Prior Authorization

    CFTR modulators require PA

    CFTR modulators (e.g., ORKAMBI, TRIKAFTA, TRIKAFTA tablets/granules) require prior authorization and are subject to LA and QL. Follow PA processes and include diagnostic/genetic evidence and prior therapy history.

    • Requirements/Limits: PA; LA; QL (as listed per product: typically 2–4 per 1 day depending on formulation)
    • Documentation should include CFTR genotype, weight/dose justification, and prior CF therapies
    Prior Authorization

    Dexcom CGM devices require PA

    Dexcom continuous glucose monitoring (CGM) devices (G6, G7 sensor/transmitter/receiver) require prior authorization and have quantity limits. Submit device documentation and medical necessity rationale with the PAR.

    • DEXCOM G6 sensor: PA; QL (3 per 30 days)
    • DEXCOM G6 transmitter: PA; QL (1 per 90 days)
    • DEXCOM G7 receiver/sensor: PA; QL (varies: receiver 1 per 365 days; sensor 3 per 30 days)
    Denial Risk

    Denial notification and appeals

    If a PAR/exception request is denied, DHMP will send the member and provider a letter outlining the decision and the member’s appeal rights. Providers should follow the appeals instructions in the denial notice or the Member Handbook.

    • Denial notice includes member rights and appeals process
    • Refer to Member Handbook or call Health Plan Services for details
    Denial Risk

    Prior authorization denial risk

    Not obtaining required prior authorization or failing to meet utilization controls (LA, ST, QL) increases the risk that a claim will be denied. Providers should verify requirements before dispensing and include complete documentation with PARs to reduce denial risk.

    • PA not obtained when required = denial risk
    • LA/ST/QL noncompliance (e.g., step failures not documented, quantity exceeded) = denial risk
    • Claims must match the formulary product name, strength, and quantity to pass limits checks
    Documentation Required

    PAR documentation requirements

    Documentation expectations for PARs include clinical chart notes, prior therapy history (failures/intolerance), labs, and any specific criteria referenced in the formulary entry. For LA or long‑acting agents, include documentation of required prior trials and rationale for the chosen formulation.

    • Providers must submit clinical information and chart notes with PARs
    • Step therapy documentation: dates, drug names, doses, duration, and reason for discontinuation or failure
    • LA antipsychotics: document prior oral/IM trials and clinical rationale for LA product
    • PA and QL requests: ensure quantity and dosing information match the formulary line
    Note

    Formulary entries include Requirements/Limits

    Formulary entries include a Requirements/Limits field showing PA, LA, QL, and ST indicators. When planning a prescription, review the entry and follow the instructions or contact Pharmacy if unclear.

    • Requirements/Limits codes: PA, LA, QL, ST
    • Formulary is updated periodically—verify the current entry before prescribing
    Step Therapy

    Step therapy documentation examples

    Examples of step therapy documentation expectations are provided in the formulary (e.g., BRIVIACT requires failure of two listed anticonvulsants; antidepressants require documented failure of specified agents). Include dates and reasons for each failed trial when submitting a PAR.

    • BRIVIACT ST: failure of two of listed anticonvulsants (document agent, dose, duration, and outcome)
    • Certain antidepressants (e.g., TRINTELLIX, vilazodone) require documented failures of listed alternatives
    Documentation Required

    Failure history documentation

    When step therapy requires failure history, the PAR must include sufficient clinical detail (which drugs were tried, dates, dosing, and reasons for failure or intolerance). Lack of this documentation frequently leads to denial.

    • Failure history should clearly show trials of required agents and clinical response
    • Onychomycosis example: JUBLIA requires failure of ciclopirox nail documented
    Billing Rule

    Claims matching and quantity limits

    Providers must ensure claims submitted for review or payment match the formulary product (name, strength, and quantity). Quantity limits that are exceeded will be flagged and may be denied unless prior authorization supports the requested amount.

    • Claims matching: product name/strength/quantity must align with formulary listing
    • Quantity limit exceedance triggers clinical review and potential denial
    Prior Authorization

    Follow PA/QL/LA procedures for flagged listings

    Follow the DHMP PA/QL/LA procedures for any formulary line that lists those requirements. If no PA or ST is listed for an item in the excerpt, standard adjudication applies — contact Pharmacy for clarification where needed.

    • When in doubt, call DHMP Pharmacy Department at 303-602-2070 or 877-357-0963
    • Follow up on denials using the appeals instructions provided with the decision

    Formulary governance and scope

    The DHMP Commercial Formulary is maintained by a multidisciplinary Pharmacy and Therapeutics Committee. Selection of formulary medications is based on FDA approval and ongoing review of safety and effectiveness, as well as consideration of indications, adverse effects, pharmacokinetics, patient adherence, outcomes, and pharmacoeconomics. The formulary operates as a closed formulary for the covered DHHA employee plans, meaning only drugs listed on the formulary are covered under the pharmacy benefit when prescribed by a provider.

    Key terms and abbreviations

    inv-84: Closed formulary definition
    DefinitionClosed formulary = only the drugs listed are covered under the pharmacy benefit
    Coverage requirementAll drugs require a prescription written by a provider to be covered
    GovernanceFormulary selections made by Pharmacy & Therapeutics Committee
    inv-85: PAR definition
    PAR (Prior Authorization Request)An exception request requiring clinical justification and supporting documentation (e.g., chart notes) to obtain coverage for a non-formulary or restricted drug
    SubmissionProviders may be asked to submit a completed PAR form to DHMP Pharmacy Department
    Use casePharmacy may trigger a PAR when claim is rejected; PAR decisions use available criteria and guidelines
    inv-86: Formulary abbreviations (PA, QL, ST, LA, PREV)
    PAPrior Authorization — member or provider must obtain prior authorization from DHMP before drug may be filled
    QLQuantity Limit — DHMP limits the amount covered per prescription or within a specified time frame
    STStep Therapy — member must first try other specified drug(s) before this drug is covered
    LALimited Access — product may require fill at Denver Health Pharmacy or PAR for non-DH pharmacies
    PREVPreventive Medication — available at $0 copay
    inv-87: LA definition
    Limited Access (LA)Indicates product is subject to restricted access (may require fill at Denver Health Pharmacy or PAR approved for non-DH pharmacies)
    ImplicationLA often appears with PA and/or QL in product rows to denote additional utilization controls
    Alternate wordingAlso used adjacent to items to signal likely prior authorization requirement per plan rules
    inv-88: ST definition
    Step Therapy (ST)Coverage requires documented failure of specified alternative agents before approval
    ExamplesST entries show required failures (e.g., failure of two listed inhaled alternatives for certain inhalers)
    DocumentationPrior trials/failures must be documented when ST is indicated
    inv-89: QL definition
    Quantity Limit (QL)Numeric dispensing limits expressed as QL (e.g., QL (4 per 1 day), QL (312.5 per 30 days))
    EnforcementDispensing limited to stated quantity per indicated time period; authorization needed for excess
    Unit examplesMay be per 1 day, per 28 days, per 30 days, per 90 days, or per year depending on product row
    inv-90: PA definition
    Prior Authorization (PA)Authorization required from DHMP before the drug may be filled; without approval DHMP may not cover the drug
    When indicatedPA appears adjacent to product names in formulary rows to signal requirement
    Provider actionProviders must submit PAR with clinical justification and supporting documentation when PA is required
    inv-91: LA alternate note
    LA alternate noteLA may indicate the drug must be filled at a Denver Health Pharmacy or that a PAR is required before fill at non-DH pharmacies
    ST associationItems labeled LA frequently also include ST language requiring failure of specified alternatives
    Plan exceptionLA does not apply to plans that do not require referrals to see outside providers
    inv-92: ST alternate note
    ST alternate noteST rows specify which alternative agents must fail (e.g., failure of ciclopirox required before JUBLIA approval)
    ScopeST may require failure of one, two, or three named agents depending on the drug (documented trial history required)
    Interaction with PA/LAST requirements often accompany LA/PA designations in product rows
    inv-93: QL alternate examples
    Topical adhesive patchesExamples show QL (3 per 1 day) for adhesive patch products (e.g., tridacaine series)
    Topical kits/creamsExamples show QL (100 per 30 days) for various topical kits/creams (lidocaine kits)
    Ciclopirox topical creamQL (3 per 1 day) shown for ciclopirox in antifungal rows
    inv-94: Common formulary annotations (PA/LA/QL/ST)
    PAPrior Authorization — member/provider must get approval before drug covered when 'PA' appears
    LALimited Access — restricted fill location or PAR requirement for non-DH pharmacies
    QLQuantity Limit — numeric cap on dispensed amount within time-frame
    STStep Therapy — prerequisite trial/failure of listed alternatives required
    inv-95: IUD definition / examples
    IUD (Intrauterine Device)Long-acting reversible contraceptives listed (e.g., MIRENA, KYLEENA, LILETTA, PARAGARD) with associated release rates/durations where shown
    ExamplesKYLEENA 17.5 mcg/24 hr (5 yrs); LILETTA 20.4 mcg/24 hr (8 yrs); PARAGARD T380A listed as copper IUD
    TieringMany IUDs/contraceptives are listed with Drug Tier = PREV indicating preventive benefit handling
    inv-96: QL label
    Label 'QL'Abbreviation QL stands for Quantity Limit — indicates max covered quantity per time period
    Displayed formatShown in product rows as QL (number per interval) e.g., QL (20 per 28 days)
    EnforcementPharmacy claims are limited to the stated QL unless prior authorization provided
    inv-97: AGE (Min) label
    Label 'AGE (Min)'Indicates minimum patient age required for coverage (e.g., PAXLOVID AGE (Min 18 Years))
    UseShown in product rows when an age restriction applies to coverage
    DocumentationPrescriptions should support patient age when AGE (Min) appears
    inv-98: LA (Limited Access) short note
    LA short noteLA = Limited Access; may require DH pharmacy fill or prior authorization for non-DH pharmacies
    Plan exceptionLA may not apply to plans that do not require referrals to outside providers
    Common pairingOften shown with PA and/or QL in formulary rows